Variable numbers of CD34+ cells can be harvested from the blood of AML patients in CR after G-CSF supported mobilization following consolidation chemotherapy. We hypothesized that a decreased ability to mobilize stem cells reflects a chemotherapy-induced reduction in the number of normal and leukemic stem cells. We therefore analyzed whether the mobilizing capacity of these patients was of prognostic significance. 342 AML-patients in first CR received daily G-CSF from day 20 of the consolidation course and underwent 1–6 aphereses to obtain a minimum dose of 2 x 106 CD34+ cells/kg. Afterwards they were randomized for autologous bone marrow (BM) or blood SCT. As a surrogate marker for the mobilizing capacity, the highest yield of CD34+ cells of a single apheresis was adopted. Patients could be categorized into four groups: no harvest (n = 76), low yield (<1 x 106 CD34+/kg; n = 50), intermediate yield (1–6.9 x 106 CD34+ cells/kg; n = 128) and high yield (7 x 106 CD34+ cells/kg; n = 88). The median follow-up was 3.4 years; 163 relapses and 16 deaths in CR were reported. Autologous blood or BM SCT was performed in 36%, 64%, 81% and 88%, respectively, of the patients assigned to the no harvest, low, intermediate and high CD34+ yield group. The 3-year disease-free survival rate was 46.7%, 65.0%, 50.4% and 26.9% (P = 0.0002) and the relapse incidence was 47.5%, 30.1%, 43.1% and 71.9% (P < 0.0001). Multivariate Cox's proportional hazards model showed that the CD34+ yield was the most important independent prognostic variable (P = 0.005) after cytogenetics. Patients with the highest mobilizing capacity have a poor prognosis due to an increased relapse incidence.

The stem cell mobilizing capacity of patients with acute myeloid leukemia in complete remission correlates with relapse risk: results of the EORTC-GIMEMA AML 10 trial / Keating, S; Suciu, S; DE WITTE, T; Zittoun, R; Mandelli, Franco; Belhabri, A; Amadori, S; Fibbe, W; Gallo, E; Fillet, G; Varet, B; Meloni, Giovanna; Hagemeijer, A; Fazi, P; Solbu, G; GIMEMA LEUKEMIA GROUP, WILLEMZE R. EORTC LEUKEMIA G. R. O. U. P.. - In: LEUKEMIA. - ISSN 0887-6924. - 17:(2003), pp. 60-67. [10.1038/sj.leu.2402782]

The stem cell mobilizing capacity of patients with acute myeloid leukemia in complete remission correlates with relapse risk: results of the EORTC-GIMEMA AML 10 trial

MANDELLI, Franco;MELONI, Giovanna;
2003

Abstract

Variable numbers of CD34+ cells can be harvested from the blood of AML patients in CR after G-CSF supported mobilization following consolidation chemotherapy. We hypothesized that a decreased ability to mobilize stem cells reflects a chemotherapy-induced reduction in the number of normal and leukemic stem cells. We therefore analyzed whether the mobilizing capacity of these patients was of prognostic significance. 342 AML-patients in first CR received daily G-CSF from day 20 of the consolidation course and underwent 1–6 aphereses to obtain a minimum dose of 2 x 106 CD34+ cells/kg. Afterwards they were randomized for autologous bone marrow (BM) or blood SCT. As a surrogate marker for the mobilizing capacity, the highest yield of CD34+ cells of a single apheresis was adopted. Patients could be categorized into four groups: no harvest (n = 76), low yield (<1 x 106 CD34+/kg; n = 50), intermediate yield (1–6.9 x 106 CD34+ cells/kg; n = 128) and high yield (7 x 106 CD34+ cells/kg; n = 88). The median follow-up was 3.4 years; 163 relapses and 16 deaths in CR were reported. Autologous blood or BM SCT was performed in 36%, 64%, 81% and 88%, respectively, of the patients assigned to the no harvest, low, intermediate and high CD34+ yield group. The 3-year disease-free survival rate was 46.7%, 65.0%, 50.4% and 26.9% (P = 0.0002) and the relapse incidence was 47.5%, 30.1%, 43.1% and 71.9% (P < 0.0001). Multivariate Cox's proportional hazards model showed that the CD34+ yield was the most important independent prognostic variable (P = 0.005) after cytogenetics. Patients with the highest mobilizing capacity have a poor prognosis due to an increased relapse incidence.
2003
AML; CD34; prognostic factor; cytogenetic; autologous stem cell transplantation
01 Pubblicazione su rivista::01a Articolo in rivista
The stem cell mobilizing capacity of patients with acute myeloid leukemia in complete remission correlates with relapse risk: results of the EORTC-GIMEMA AML 10 trial / Keating, S; Suciu, S; DE WITTE, T; Zittoun, R; Mandelli, Franco; Belhabri, A; Amadori, S; Fibbe, W; Gallo, E; Fillet, G; Varet, B; Meloni, Giovanna; Hagemeijer, A; Fazi, P; Solbu, G; GIMEMA LEUKEMIA GROUP, WILLEMZE R. EORTC LEUKEMIA G. R. O. U. P.. - In: LEUKEMIA. - ISSN 0887-6924. - 17:(2003), pp. 60-67. [10.1038/sj.leu.2402782]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/89463
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 59
  • ???jsp.display-item.citation.isi??? 55
social impact